ReviewJournal of mammary gland biology and neoplasia2000
Biological features of premalignant disease in the human breast.
Review in Journal of mammary gland biology and neoplasia, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 55 citations in OpenAlex.
- Development and Validation of Dynamic 5-Year Breast Cancer Risk Model Using Repeated Mammograms.JCO clinical cancer informatics · 2024Article
- Chaperone-assisted E3 ligase CHIP: A double agent in cancer.Genes & diseases · 2022Review
- Modeling Human Ductal Carcinoma In Situ in the Mouse.Journal of mammary gland biology and neoplasia · 2018Review
- Epigenetic Silencing ofJournal of breast cancer · 2017Article
- Article
- Diverse roles of C-terminal Hsp70-interacting protein (CHIP) in tumorigenesis.Journal of cancer research and clinical oncology · 2014Review
- Assessment of DNA methylation status in early stages of breast cancer development.British journal of cancer · 2013Article
- ESR1 amplification is rare in breast cancer and is associated with high grade and high proliferation: a multiplex ligation-dependent probe amplification study.Cellular oncology (Dordrecht, Netherlands) · 2011Article
- Role of ERalpha in the differential response of Stat5a loss in susceptibility to mammary preneoplasia and DMBA-induced carcinogenesis.Carcinogenesis · 2010Article
- A human breast cell model of preinvasive to invasive transition.Cancer research · 2008Article
- Clinical opinion: the biologic and pharmacologic principles for age-adjusted long-term estrogen therapy.MedGenMed : Medscape general medicine · 2006Review
- Modeling dynamic reciprocity: engineering three-dimensional culture models of breast architecture, function, and neoplastic transformation.Seminars in cancer biology · 2005Review
- Protein 4.1B expression is induced in mammary epithelial cells during pregnancy and regulates their proliferation.Oncogene · 2005Article
- Validation of transgenic models of breast cancer: ductal carcinoma in situ (DCIS) and Brca1-mutation-related breast cancer.Breast cancer online : BCO · 2005Article
- Loss of p53 function accelerates acquisition of telomerase activity in indefinite lifespan human mammary epithelial cell lines.Oncogene · 2003Article
- Culture models of human mammary epithelial cell transformation.Journal of mammary gland biology and neoplasia · 2000Review
- The preneoplastic phenotype in murine mammary tumorigenesis.Journal of mammary gland biology and neoplasia · 2000Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Most human invasive breast cancers (IBCs) arise from preexisting benign lesions. There are many types of benign lesions in the human breast and only a few appear to have significant premalignant potential (atypical hyperplasias and in situ carcinomas). These lesions are relatively common and only a small proportion progress to IBC. They are currently defined by their histological features and their prognosis is imprecisely estimated from indirect evidence based on epidemiological studies. Although lesions within specific categories look alike, they must possess morphologically silent biological differences motivating some to remain stable and others to progress. Understanding the biological changes responsible for the development and progression of premalignant disease is a very active area of medical research. Progress in this area may provide new opportunities for breast cancer prevention by providing strategies to treat premalignant lesions before they develop or become cancerous. A large number of biological features have been evaluated in this setting during the past decade. This review discusses a few features that appear to be particularly important and have been studied in a relatively comprehensive manner.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.